Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;108(34-35):578-82.
doi: 10.3238/arztebl.2011.0578. Epub 2010 Aug 29.

Pancreatic enzyme therapy

Affiliations
Review

Pancreatic enzyme therapy

Joachim Mössner et al. Dtsch Arztebl Int. 2010 Aug.

Abstract

Background: Treatment with pancreatic enzymes must be based on an understanding of the normal physiology and pathophysiology of exocrine pancreatic function, as well as of the diseases that cause exocrine pancreatic insufficiency of either a structural or a functional type. These include chronic pancreatitis, pancreatic cancer, cystic fibrosis, pancreaticocibal asynchrony after gastric or pancreatic surgery, and celiac disease.

Methods: Selective review of the literature.

Results: Exocrine pancreatic insufficiency can cause meteorism, diarrhea, steatorrhea, and weight loss. All of these manifestations are non-specific except steatorrhea. Enzyme supplementation is indicated only for the treatment of demonstrated pancreatic dysfunction; unfortunately, however, no sensitive and specific pancreatic function tests are currently available. As a result, pancreatic enzyme supplementation is considered to be indicated on pragmatic grounds when, for example, the patient is suffering from diarrhea and weight loss and has been demonstrated to have a disease leading to exocrine pancreatic insufficiency. To be acceptable for clinical use, a pancreatin preparation must satisfy the following criteria: it must be enterically coated, so that it will not be destroyed by gastric acid; mix well with gastric chyme; exit the stomach simultaneously with chyme; and be rapidly released from its enteric coating upon entering the duodenum. Although there have been no large-scale, randomized comparative studies of different types of pancreatin preparation, the current clinical preference is for enterically coated micropellets or minitablets with a diameter of 2 mm or less. The initial dosage is 20 000 to 40 000 units of lipase taken once or twice per meal, with dose adjustment afterward as needed. The dose can be raised, and a proton-pump inhibitor can be added on.

Conclusion: There is still no simple test that can be used to diagnose pancreatic exocrine insufficiency with certainty. The treatment is symptomatic; its goals are to lessen steatorrhea and reverse weight loss.

PubMed Disclaimer

Figures

Figure
Figure
Physiological processes during food digestion

References

    1. Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control A review. Physiol Behav. 2008;95:271–281. - PubMed
    1. Keim V, Klar E, Poll M, Schoenberg MH. Postoperative care following pancreatic surgery: surveillance and treatment. Dtsch Arztebl Int. 2009;106:789–794. - PMC - PubMed
    1. Rosendahl J, Witt H, Szmola R, Bhatia E, Ózsvári B, Landt O, et al. Chymotrypsin C (CTRC) alterations that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet. 2008;40:78–82. - PMC - PubMed
    1. Teich N, Mössner J. Hereditary pancreatitis. Best Pract Res Clin Gastroenterol. 2008;22:115–130. - PubMed
    1. Ammann RW, Muellhaupt B, Meyenberger C, Heitz PU. Alcoholic nonprogressive chronic pancreatitis: prospective long-term study of a large cohort with alcoholic acute pancreatitis (1976-1992) Pancreas. 1994;9:365–373. - PubMed

MeSH terms